CK2 is a ubiquitously expressed, constitutively active Ser/Thr protein kinase, which is considered the most pleiotropic protein kinase in the human kinome. Such a pleiotropy explains the involvement of CK2 in many cellular events. However, its predominant roles are stimulation of cell growth and prevention of apoptosis. High levels of CK2 messenger RNA and protein are associated with CK2 pathological functions in human cancers. Over the last decade, basic and translational studies have provided evidence of CK2 as a pivotal molecule driving the growth of different blood malignancies. CK2 overexpression has been demonstrated in nearly all the types of hematological cancers, including acute and chronic leukemias, where CK2 is a key regulator of signaling networks critical for cell proliferation, survival and drug resistance. The findings that emerged from these studies suggest that CK2 could be a valuable therapeutic target in leukemias and supported the initiation of clinical trials using CK2 antagonists. In this review, we summarize the recent advances on the understanding of the signaling pathways involved in CK2 inhibition-mediated effects with a particular emphasis on the combinatorial use of CK2 inhibitors as novel therapeutic strategies for treating both acute and chronic leukemia patients.

中文翻译：

---

CK2在急性和慢性白血病中的治疗靶向。

CK2是一种普遍表达的，组成型活性的Ser / Thr蛋白激酶，被认为是人类激酶组中最具多效性的蛋白激酶。这种多效性解释了CK2参与许多细胞事件。然而，其主要作用是刺激细胞生长和防止细胞凋亡。CK2信使RNA和蛋白的高水平与人类癌症中CK2的病理功能有关。在过去的十年中，基础研究和转化研究提供了CK2作为驱动不同血液恶性肿瘤生长的关键分子的证据。几乎在所有类型的血液系统癌症（包括急性和慢性白血病）中都证明了CK2的过度表达，其中CK2是信号传导网络的关键调节因子，对细胞增殖，存活和耐药性至关重要。这些研究结果表明，CK2可能是白血病的重要治疗靶点，并支持使用CK2拮抗剂开展临床试验。在这篇综述中，我们总结了对CK2抑制介导的效应所涉及的信号通路的理解的最新进展，特别强调了CK2抑制剂作为治疗急性和慢性白血病患者的新型治疗策略的组合使用。